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Other ways of estimating the number of patients retained on therapy are needed. Development of electronic data system capacity may be a solution, but this is fraught with challenges in low-technology settings. In addition to the hardware costs and the need for a sustained electricity supply, the electronic system needs well-trained information technology personnel to routinely monitor performance and resolve problems. Another possible option is using pharmacy records to streamline the monitoring process. 6, 7 Pharmacy stock card information on drug dispensation, if well kept, could be used as an indicator of treatment retention over a defi ned time period.
The objectives of this pilot study were 1) to determine whether pharmacy records can provide comparable estimates of patients retained on ART, including numbers retained on different regimens, at different levels of the health system, and 2) to examine the workload and time taken to determine retention on therapy comparing use of pharmacy records with clinic cohort analysis. Findings from this pilot study can inform the feasibility of using pharmacy stock cards to simplify the process of monitoring the number of patients alive and on ART in low-resource settings.
METHODS

Study setting
This pilot study used a purposeful sampling technique to select fi ve ART facilities 1) that represent various levels of medium-to large-sized ART facilities in the South-East Zone, 2) that followed >1000 patients on ART (i.e., not a small-sized cohort, where aggregating cohort data is not diffi cult and does not require a lot of time), and 3) that were selected based on the explicit agreement of the DHA supervision teams and the District Health Management Teams in the SouthEast Zone (population 3.2 million).
Data were collected from one peri-urban health centre, three rural secondary referral hospitals and one
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Health solu ons for the poor Results: There is wide variability between ART clinic cohort data and pharmacy data to determine treatment retention due to divergence in data at sites with large numbers of patients. However, there is a non-significant trend towards agreeability between the two methods (intra class correlation coefficient > 0.9; P > 0.05). Pharmacy stock card monitoring is more time-efficient than quarterly ART data aggregation (81 min vs. 573 min).
Conclusion:
In low-resource settings, pharmacy records could be used to improve drug forecasting and estimate ART retention in a more time-efficient manner than quarterly data aggregation; however, a necessary precondition would be capacity building around pharmacy data management, particularly for large-sized cohorts.
T he scale-up of antiretroviral therapy (ART) in lowand middle-income countries is one of the most remarkable public health achievements of the last decade. Routine monitoring of patients who have started on ART and those who are retained on ART is crucial for measuring programme success. 1 Consistent access to data on the number of new patients starting ART and the number retained on treatment over a specifi c period of time is necessary for forecasting for commodities, 2 provides a yardstick by which to assess progress, and helps to determine whether funds are used effectively.
In Malawi, like other countries in southern Africa, rapid scale-up to over 350 000 patients ever enrolled has challenged the capacity of the public health infrastructure to effectively monitor and retain large numbers of patients. 3, 4 Currently, the Department of HIV/AIDS (DHA) at the Malawi Ministry of Health (MOH) compiles monitoring and evaluation data on the ART programme through quarterly supervisions, during which 10 teams of ART providers (31 individuals from the MOH and from non-governmental orga-
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Monitoring and evaluation of HIV programmes 33 urban tertiary referral centre. The central hospital clinic is an MOH clinic that uses an electronic patient data management system supported by Dignitas International, a Canadian medical NGO. During the period of data collection, the central hospital transitioned from data entry of paper data into a database to a direct entry electronic patient management system (Baobab Malawi). All other sites used paper-based management, and service delivery was provided solely by the Malawi MOH. All sites provided ART services as per standardised national guidelines. 8 
Data collection
In all ART facilities, quarterly cohort reports were collected from clinic-based paper or electronic records for both Quarter 4 (1 October to 31 December 2010) and Quarter 1 (1 January to 31 March 2011). Data on 'the number of new patients registered, including new ART initiations and transfer-in patients', and 'the number of patients retained on therapy at the end of a quarter' were extracted and calculated from the ART register. The number retained on therapy was also categorised by type of regimen (fi rst-line, a lternative fi rst-line and second-line). The number of full-time equivalent (FTE) staff needed to conduct the analysis was determined by timing all staff responsible for compiling cohort reports during the quarterly supervision. The number of ART continuation bottles in the pharmacy at all sites was documented at the start and end of a specifi c quarter from pharmacy stock cards for the following drugs: stavudinel amivudine-nevirapine (d4T-3TC-NVP), zidovudine (AZT)-3TC-NVP, AZT-3TC, D4T-3TC, efavirenz (EFV), tenofovir, 3TC, NVP, d idanosine, abacavir and ritonavir-lopinavir. Data for reallocation or expiry were also recorded from stocks and delivery notes and were used to calculate the total bottles dispensed to patients in the evaluation period. Although dispensing intervals varied, the average rate of dispensing per patient during this period was assumed to be stable over time. In the regimen-specifi c analysis for number of people retained on various alternative fi rst-line regimens, the amount of fi rst-line AZT-3TC was used as a proxy for patients on AZT-3TC + EFV as alternative fi rst-line treatment (for prevention of mother-to-child transmission of HIV, fi rst-and second-line stocks of AZT-3TC are recorded on separate stock cards), and the amount of d4T-3TC was used as a proxy for patients on d4T-3TC + EFV. For alternative fi rst-line retention calculations, an adjustment for number of new patients (i.e., [total number of ART tins used over 3 months − (1.5 × number of new patients enrolled during the quarter)/3]) was not used, as most patients remain on fi rst-line treatment during the fi rst 3 months. This adjustment was made to calculate the retention of patients on fi rst-line treatment, i.e., d4T-3TC-NVP.
Data analysis
Data were excluded in measurement accuracy from Mulanje DH Quarter 1, 2011, due to missing pharmacy stock cards. The timing of workload of the supervision team for the Mulanje DH data collection was not observed due to scheduling issues between the study team and the supervision team. The ART cohort data collection for Zomba Central Hospital was terminated early due to discrepancies in data in Quarter 4, 2010, as a result of data system migration.
Measurement accuracy, comparing both methods of determining retention on treatment, was assessed by calculating the i ntraclass correlation coeffi cient (ICC) and visually exploring Bland-Altman plots. All statistical analyses were conducted using Intercooled Stata version 9.2 (Stata Corp, LP, College Station, TX, USA); the signifi cance level was fi xed at P < 0.05.
Ethics approval
This pilot study was approved by the Ethics Advisory Group of the International Union Against Tuberculosis and Lung Disease, Paris, France, and sent to the Malawi National Health Sciences Research Council for oversight. Table 1 demonstrates the number of patients retained on ART based on data collected from fi ve ART facilities over two quarters. The range in 'precision' (determined by the number of people retained on treatment using pharmacy data/clinic cohort data) varied from 78% to 150% in Quarter 4, 2010, and from 28% to 103% in Quarter 1, 2011. The number of ART bottles dispensed was stratifi ed according to ART regimen, with results in Table 2 again demonstrating wide variability in 'precision'. For second-line regimens, small numbers prevented any meaningful comparison. Table 3 and the Figure demonstrate statistical measures of agreement between the two methods of determining retention on treatment, as there is no gold standard for the actual number of patients * ICC > 0.7 denotes good agreeability between methods; however, statistically none of the ICCs were shown to be significant due to wide CIs. ICC = intraclass correlation coefficient; CI = confidence interval; d4T-3TC-NVP = stavudine-lamivudine-nevirapine; AZT = zidovudine; EFV = efavirenz. Table 4 shows the time and workload required to compile clinic cohort reports and pharmacy stock data. The range of patients followed in the clinics varied from 1323 to 15 269. It took on average 573 min (range 40-1473 min) to compile the clinic cohort report. In contrast, estimation of cohort data from pharmacy stock cards took only 81 min on average (range 33-185 min). More staff were also required to complete the ART cohort report (range 2-8 persons) compared with the pharmacy stock cards (1-3 persons).
RESULTS
Comparison of quarterly ART clinic cohort report and pharmacy stock cards
Workload and time taken in compiling cohort report
There was a signifi cant reduction in time to complete cohort reporting when electronic data reporting was used, and that was only at the largest site, Zomba Central Hospital. Using an NGOsupported paper-to-electronic data transfer method and an Access database in Quarter 4, 2010, the time to generate a report was 106 min. Using the Baobab Electronic Data System in Quarter 1, 2011, which has automated macros for quarterly supervision reporting and is direct entry by provider, the time to generate a report was 40 min. These do not account for the time and human resources required to clean the electronic data, which is substantial using either method of electronic data management.
DISCUSSION
This is one of the fi rst studies to explore the feasibility of using pharmacy stock cards to simplify the process of monitoring the number of patients alive and on ART in low-resource settings. First, the study demonstrates the limitations of using operational data in research with respect to the reliability and accuracy of the data. For example, data had to be excluded from one site in one quarter due to missing stock cards. In addition, there were concerns about the reliability of the cohort data generated at the largest site due to problems during migration of data from an old electronic data system to a new system. One would have expected the data to be more accurate at the smaller sites; however, there was clearly wide variation in precision between sites and also within sites at two different time points, independent of the size of the cohort. The inconsistencies in paper data refl ect fi ndings from a recent paper published from Malawi, which looked at the extent of inaccuracies between electronic records and paper registers in fi ve health facilities and found up to 24% of total case registrations
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missing in one hospital and major discrepancies in the number of deaths recorded at two sites. 9 This study strongly suggests that using pharmacy stock data to determine the number of patients retained on treatment may be cost-effective due to the reduction in the time health care workers spend estimating the numbers of patients on ART. Capacity building in improving the accuracy of pharmacy stock data is warranted, as it may be a far more cost-effective way to manage commodities, monitor the number of patients on treatment and fl ag defaulters than resource-intensive quarterly clinic cohort monitoring. Data from a study looking at the use of a computerised pharmacy tracking system (iDART) in South Africa to identify loss to follow-up at a community-based ART clinic suggest that a wellmanaged pharmacy system can also be used to detect potential defaulters and fl ag them for recall. 10 Although the pharmacy stock cards appear, overall, to be a viable method of assessing ART patient retention, the data demonstrate that signifi cant differences between the pharmacy and ART registers remain to be addressed. Although the ICC for almost all regimens was upwards of 0.9, which suggests good agreeability between the two methods, none of the results were signifi cant (P < 0.05), due to a wide CI. The Bland-Altman plots suggest that FIGURE Cohort vs. pharmacy data: number retained on treatment. Bland-Altman plots displaying the agreement between measuring number retained on treatment comparing ART cohort data and pharmacy stock card data; the x-axis is 'the number of patients as a mean of both methods' and the y-axis is 'the difference in number of patients between methods'. Correlation R = 0.21 (P = 0.58). Slope = −0.067 (P = 0.58). Intercept = 370.4 (P = 0.59). A. There appears to be greater agreement when the numbers retained on treatment are lower, with higher divergence at the sites with larger cohorts. Correlation R = 0.21 (P = 0.58). Slope = −0.067 (P = 0.58). Intercept = 370.4 (P = 0.59). B. The association of agreement with size of cohort holds true even with results disaggregated by specific type of regimen. a. Cohort data vs. pharmacy data: number retained on d4T-3TC-NVP. Correlation R = 0.16 (P = 0.67), slope = −0.069 (P = 0.68), intercept = 375 (P = 0.58). b. Cohort data vs. pharmacy data: number retained on AZT-3TC-NVP. Correlation R = 0.84 (P < 0.05), slope = −0.347 (P < 0.05), i ntercept = 8 (P = 0.83). c. Cohort data vs. pharmacy data: number retained on AZT-3TC-EFV. Correlation R = 0.55 (P = 0.12), Slope = 0.547 (P = 0.12), intercept = 2 (P = 0.86). d. Cohort data vs. pharmacy data: number retained on d4T-3TC-EFV. Correlation R = 0.37 (P = 0.29), slope = −0.162 (P = 0.29), intercept = −12 (P = 0.65). 
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this wide variability is primarily due to divergence in data at the sites with large cohorts. Our data do not allow us to determine whether the inaccuracies are due to errors in the ART cohort report or the pharmacy stock records as the cohort size gets larger. However, the Malawi DHA uses the cohort analysis performed by the quarterly supervision teams as the 'gold standard' in this setting, and most sites were awarded 'Certifi cates of Excellence' from the Malawi MOH based on their assessment of the quality of the cohort data. This implies an urgent need for pharmacy management strengthening. Pharmacy operations for ART drug dispensation vary according to facility type, and this may contribute to discrepancies. In district hospitals, all ART drugs are stored in the main district pharmacy, and drug disbursement and transfers are documented on stock cards. When the ART clinics request drugs, the drugs are transferred to a separate location within the main district pharmacy, e.g., a locked cabinet, to signify their assignment for a specifi c location. Drugs are then collected from this location and brought to the ART clinic for dispensing in clinic rooms. Each dispensing room has an ART register that is updated every time the nurse dispenses ART drugs to a patient. The data for this model were collected from the main pharmacy, as the lockable cabinets did not contain stock cards. Lack of documentation of the drugs collected from cabinets made it hard to confi rm whether all drugs dispensed from the main pharmacy were actually given to patients in the ART facility, and thus may have led to an overestimate of ART retention. It is of note that since the study results were collected, the Pharmacy Coordinator for Dignitas Inter national has had multiple mentoring sessions with pharmacy staff at the rural hospital sites on both record keeping and other drug management issues. In addition, a nurse has been allocated at a site identifi ed as having stock management issues to assist the pharmacy in updating their stock cards on ART and other HIV-related drugs.
Finally, although the implementation and running costs of electronic patient management systems are high, the promotion of electronic systems in high-burden ART facilities is advisable purely for data management effi ciency. Our data confi rm that it is also time-saving for generating data cohort reports. The fi ndings from the accuracy of pharmacy cohort data reporting suggest that a wise investment in capacity building in pharmacy data management should also include concurrent development of electronic pharmacy data monitoring for sites with high numbers of patients, given the divergence of paper-based pharmacy records at those sites.
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Marco de referencia: La rápida ampliación de escala de la administración del tratamiento antirretrovírico (ART) ha planteado al sistema de salud de Malawi el reto del seguimiento eficaz de un gran volumen de pacientes. Objetivo: Comparar dos métodos de calcular la permanencia de los pacientes en el tratamiento, a saber los datos agregados trimestrales del consultorio de ART y las tarjetas de reserva de la farmacia. Método: Entre octubre del 2010 y marzo del 2011 se extrajeron los datos sobre los resultados del ART de los instrumentos de seguimiento de cinco centros de atención. Se obtuvieron además los datos de farmacia sobre el consumo de medicamentos antirretrovíricos. Se observó y se cuantificó la cantidad de trabajo que exigía cada técnica. Se calculó el coeficiente de correlación intraclase y mediante gráficos de Bland-Altman se comparó la concordancia de ambos métodos en la determinación de la permanencia en tratamiento. Resultados: Se observó una gran variabilidad de la permanencia de los pacientes cuando se midió mediante los datos de las cohortes de los consultorios de ART o con los datos de la farmacia. La causa de la discordancia fue la divergencia de los datos en los centros que atendían un gran volumen de pacientes. Se observó, no obstante, una tendencia sin significación estadística hacia la concordancia de ambos métodos (coeficiente de correlación intraclase > 0,9; P > 0,05). El seguimiento realizado en función de las tarjetas de reserva de farmacia es más rápido que cuando se calcula con la agregación de datos de las cohortes (81 minutos contra 573 minutos). Conclusión: En entornos con escasos recursos, es más eficiente utilizar las tarjetas de farmacia que los datos agregados trimestrales con el objeto de mejorar la previsión de medicamentos y calcular la permanencia de los pacientes en el tratamiento. La utilización de los registros de farmacia exigiría aumentar la capacidad de gestión de datos en las farmacias, sobre todo en el caso de cohortes de gran tamaño.
